IL18 and acute kidney injury: In recent clinical trials, cell cycle arrest biomarkers as tissue inhibitor of metalloproteinase 2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) have been demonstrated to be effective in the early detection of AKI (169–171), and to perform better than other biomarkers such as NGAL, IL-18 (172), L-FABP, and KIM-1 (173, 174).